Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and POETYK PSO-LTE Trials

被引：0
|
作者：
Lebwohl, Mark [1 ]
Warren, Richard B. [2 ]
Kircik, Leon [1 ]
Colston, Elizabeth [3 ]
Hippeli, Lauren [3 ]
Napoli, Andrew [3 ]
Kisa, Renata M. [3 ]
Banerjee, Subhashis [3 ]
Menter, Alan [4 ]
Thaci, Diamant [5 ]
Blauvelt, Andrew [6 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY USA
[2] Univ Manchester, Salford Royal NHS Fdn Trust, Dermatol Ctr, NIHR Manchester Biomed Res Ctr, Manchester, England
[3] Bristol Myers Squibb, New York, NY USA
[4] Baylor Univ, Med Ctr, Waco, TX USA
[5] Univ Lubeck, Lubeck, Germany
[6] Oregon Med Res Ctr, Portland, OR USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
43851
引用
收藏
页码：AB35 / AB35
页数：1
相关论文
共 50 条
  • [1] Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials
    Armstrong, April W.
    Lebwohl, Mark
    Warren, Richard B.
    Sofen, Howard
    Morita, Akimichi
    Paul, Carle
    Papp, Kim A.
    Colombo, Matthew J.
    Scotto, Julie
    Vaile, John
    Zhuo, Joe
    Vritzali, Eleni
    Berger, Victoria
    Schroeder, Georgene
    Banerjee, Subhashis
    Thaci, Diamant
    Strober, Bruce
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2025,
  • [2] Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program
    Spelman, Lynda
    Warren, Richard B.
    Sofen, Howard
    Imafuku, Shinichi
    Blauvelt, Andrew
    Toms, Jessica
    Buck, Alex
    Banerjee, Subhashis
    Menter, Alan
    Szepietowski, Jacek C.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 28 - 28
  • [3] DEUCRAVACITINIB LONG-TERM EFFICACY AND SAFETY IN PLAQUE PSORIASIS: 2-YEAR RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM
    Warren, R. B.
    Sofen, H.
    Imafuku, S.
    Szepietowski, J.
    Blauvelt, A.
    Spelman, L.
    Colston, E.
    Toms, J.
    Buck, A.
    Banerjee, S.
    Menter, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 841 - 841
  • [4] Deucravacitinib Long-term Efficacy and Safety in Plaque Psoriasis: 2-Year Results from the Phase 3 POETYK PSO Program
    Warren, Richard
    Sofen, Howard
    Imafuku, Shinichi
    Szepietowski, Jacek C.
    Blauvelt, Andrew
    Spelman, Lynda
    Toms, Jessica
    Buck, Alex
    Banerjee, Subhashis
    Menter, Alan
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4230 - 4232
  • [5] Deucravacitinib (DEUC) Long-Term Efficacy with Continuous Treatment in Plaque Psoriasis: 2-Year Results from the Phase 3 POETYK PSO Study Program
    Thaci, Diamant
    Lebwohl, Mark
    Warren, Richard B.
    Sofen, Howard
    Imafuku, Shinichi
    Paul, Carle
    Szepietowski, Jacek
    Spelman, Lynda
    Passeron, Thierry
    Colston, Elizabeth
    Hippeli, Lauren
    Napoli, Andrew
    Kisa, Renata
    Banerjee, Subhashis
    Menter, Alan
    Blauvelt, Andrew
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 120 - 121
  • [6] Deucravacitinib in Plaque Psoriasis: 4-Year Efficacy Results by Prior Biologic Treatment in the Phase 3 POETYK PSO-1, PSO-2, and Long-Term ExtensionTrials
    Warren, Richard
    Armstrong, April W.
    Imafuku, Shinichi
    Morita, Akimichi
    Paul, Carle
    Augustin, Matthias
    Passeron, Thierry
    Kircik, Leon
    Vritzali, Eleni
    Scharnitz, Thomas
    Schroeder, Georgene
    Banerjee, Subhashis
    Strober, Bruce
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2310 - 2312
  • [7] DEUCRAVACITINIB IN PLAQUE PSORIASIS: 2-YEAR LABORATORY RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM
    Korman, N. J.
    Passeron, T.
    Gordon, K. B.
    Okubo, Y.
    Bagel, J.
    Sofen, H.
    Warren, R. B.
    Bhatia, N.
    Spelman, L.
    Winthrop, K.
    Hippeli, L.
    Kisa, R. M.
    Banerjee, S.
    Thaci, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1774 - 1775
  • [8] Deucravacitinib in plaque psoriasis: Safety and efficacy through 3 years in Japanese patients in the phase 3 POETYK PSO-1, PSO-4, and LTE trials
    Morita, Akimichi
    Imafuku, Shinichi
    Tada, Yayoi
    Okubo, Yukari
    Habiro, Katsuyoshi
    Tsuritani, Katsuki
    Banerjee, Subhashis
    Hoyt, Kim
    Kisa, Renata M.
    Ohtsuki, Mamitaro
    JOURNAL OF DERMATOLOGY, 2025,
  • [9] DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN MODERATE TO SEVERE PLAQUE PSORIASIS: 52-WEEK EFFICACY RESULTS FROM THE PHASE 3 POETYK PSO-1 AND POETYK PSO-2 TRIALS
    Warren, R. B.
    Armstrong, A.
    Gooderham, M.
    Strober, B.
    Thaci, D.
    Imafuku, S.
    Sofen, H.
    Spelman, L.
    Korman, N. J.
    Zheng, M.
    Colston, E.
    Throup, J.
    Kundu, S.
    Kisa, R.
    Banerjee, S.
    Blauvelt, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1570 - 1571
  • [10] Deucravacitinib Improves Psoriasis Symptoms and Signs Diary Domain Scores in Patients With Moderate to Severe Plaque Psoriasis: Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Studies
    Armstrong, April W.
    Strober, Bruce
    Gordon, Kenneth
    Zhuo, Joe
    Becker, Brandon
    Kisa, Renata
    Throup, John
    Kim, Jonghyeon
    Dirschka, Thomas
    Papp, Kim Alexander
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 24 - 25
12345